NCT07651020Completed
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Here's a polished version of the text: "This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian cancer, head and neck tumors, colorectal cancer, melanoma, etc., as well as healthy volunteers. Using a targeted LRRC15-specific SPECT imaging agent, SPECT/CT imaging is performed to achieve the following objectives: For malignant tumor patients: To support disease diagnosis and staging. Diagnostic performance will be evaluated against the gold standard of pathological diagnosis, clarifying the presence or absence of lesions and determining their location and nature. To enable accurate staging and assess tumor burden by comparison with \[18F\]FDG PET/CT, thereby aiding in the determination of treatment plans. For healthy volunteers: To conduct pharmacokinetic analysis, elucidating the distribution, metabolism, and safety profile of the agent in the body."
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1 (actual)
- First submitted
- 11 Jun 2026
- Start date
- 31 Jul 2025
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Melanoma, Sarcoma, Glioblastoma, Lung cancer, Pancreatic cancer, Colorectal cancer, Ovarian cancer
- NCT number
- NCT07651020
What you commit to
- Study type: Observational
- Participants enrolled: 1
- From 31 Jul 2025 to the primary completion date, 28 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances;
- Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.
Lab values
- Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol/L prior to \[¹⁸F\]FDG injection;
Other
- Any subject meeting any of the following baseline criteria will be excluded from the study:
- Inability to tolerate or complete SPECT/CT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.);
- Patients deemed by the investigator to have poor expected compliance;
- Pregnant or lactating (nursing) women;
Who the study is looking for
- Each subject must meet all of the following inclusion criteria to be eligible for study enrollment:
- The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);
- Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;
- Adult patients or healthy volunteers, aged 18 years or older, male or female;
- Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;
- Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;
- Must meet any other protocol-specified inclusion criteria.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wuhan Union Hospital, China Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.